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INTRODUCTION
Human herpesvirus-6 (HHV-6) is widely distributed in the
general population — 95% of individuals in the world have
acquired HHV-6 infection at some point in their lives. The
primary infection usually occurs in the early years of life
and remains latent throughout life (Costa et al., 2011).
Originally HHV-6 was divided into two groups, variant A
(HHV-6A) and variant B (HHV-6B). However, in 2012 the
International Committee on Taxonomy of Viruses (ICTV)
decided to recognise both variants as different species
(Ablashi et al., 2014).
HHV-6 is known to have strong immunomodulating proper-
ties, which could affect the host during a long period of
time and contribute to several autoimmune disorders, in-
cluding autoimmune haemolytic anaemia/neutropenia (Ya-
gasaki et al., 2011), autoimmune acute hepatitis (Grima et
al., 2008) and multiple sclerosis (Chapenko et al., 2003;
Tejada-Simon et al., 2003). Recent studies pay more and
more attention to the possible involvement of human
herpesvirus-6 in autoimmune thyroiditis (AIT) development
(Rizzo et al., 2016; Caselli et al., 2017; Sultanova et al.,
2017). The contribution to several autoimmune diseases and
its widespread distribution, make HHV-6 an important
threat to overall health and quality of life.
Our recent study showed a very high frequency rate (99%)
of HHV-6B genomic sequence detection in AIT patient thy-
roid gland tissues in comparison to the control group sam-
ples (77%) and 41% of AIT patient tissues contained mark-
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The aim of this study was to investigate the possibility of using monocytes/macrophages as me-
diators in human herpesvirus-6 (HHV-6) infection of thyroid gland tissues in autoimmune thyroidi-
tis (AIT). Seventy-three AIT patients were enrolled in this study. The control group consisted of 80
blood donors. Monocyte/macrophage isolation for AIT patient samples was performed by adher-
ence. HHV-6 was detected in peripheral blood mononuclear cell (PBMC) DNA samples using
nested polymerase chain reaction (nPCR). Gene expression of HHV-6 active infection marker
(U79/80) and chemokine receptors (U12, U51) in patient monocyte/macrophage samples and
blood donor PBMC samples was detected using reverse-transcription PCR. HHV-6 viral load was
detected by using quantitative-PCR technique. The HHV-6 genomic sequence was found signifi-
cantly more frequently among AIT patient than control group samples. Markers of active infection
were found in 8 AIT patient monocyte/macrophage samples (11%) and in none of control group
PBMC samples. HHV-6 U51 mRNA expression was detected only in AIT patient samples (2/24
previously positive for HHV-6). Since HHV-6 genomic sequences were found significantly more
frequently in AIT patient samples and active infection markers were found in patient mono-
cytes/macrophages, our results suggest that monocytes/macrophages may be used by HHV-6 as
mediators for thyroid gland infection.
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ers of HHV-6 active infection (presence of HHV-6 U79/80
mRNA), while only 6% contained the marker in the control
group (Sultanova et al., 2017). Another finding of our pre-
vious studies was a significant difference in the presence of
HHV-6 genomic sequence in thyroid gland tissues and pe-
ripheral blood mononuclear cell subpopulations, where no
signs of virus presence were found in CD4+/CD8+ T lym-
phocytes, which are considered as the main target cells for
HHV-6 (Sultanova et al., 2016). The absence of HHV-6 in
the main T cell population led to a theory that HHV-6 could
potentially persist in monocytes/macrophages. There are
studies that indicate monocytes/macrophages as important
sites for HHV-6 persistence during acute infection and puta-
tive chemokine receptor HHV-6 U12 and U51 gene expres-
sion has been detected in these cells (Kondo et al., 2002;
Murakami et al., 2010). HHV-6 U12 and U51 gene expres-
sion could help HHV-6 to avoid the immune response and
to use monocytes/macrophages as vectors for infection of
solid tissues during immune cell migration to the site of in-
flammation (Kondo et al., 2002).
The aim of this study was to determine the presence, activ-
ity and immunomodulating potential of HHV-6 in mono-
cytes/macrophages isolated from patients with autoimmune
thyroiditis.
MATERIALS AND METHODS
Patients used in the study. Seventy-three patients with
autoimmune thyroiditis (AIT) were enrolled in this study.
The patient group included three males (4%) and 70 females
(96%), with median age of 52 (Interquartile range [IQR]:
42–60). The control group included 80 blood donors, of
whom 50 were males (62%) and 30 females (38%), with
median age of 32 (IQR: 26–39).
The permission to conduct the research was received from
Rîga Stradiòð University (RSU) Ethics Committee, and all
participants in the study gave their written consent to the
examinations. Samples were received from Rîga Eastern
Clinical University Hospital.
Peripheral blood mononuclear cell isolation. Peripheral
blood mononuclear cells (PBMC) were isolated using Fi-
coll/Hypaque 1.077 g/ml (Sigma Chemical Co, Munich,
Germany) by the standard isolation protocol (Boyum,
1968).
For AIT patients monocyte isolation was performed by ad-
herence, 10–15·106 PBMC were seeded per T25 cell culture
flask, and allowed to adhere in a 5% CO2 incubator at 37 °C
for two hours in 5 ml of culture medium (CM), which con-
sisted of RPMI-1640 (Gibco, Germany) supplemented with
10% foetal bovine serum (Gibco, USA), 2 mM L-
glutamine (Sigma Chemical Co, Munich, Germany), 100
U/ml penicillin, and 100 µg/ml streptomycin (Sigma
Chemical Co, Munich, Germany). Non-adherent cells were
removed and the adherent cells were carefully washed,
twice with CM. Adherent cells were left for 24 hours in a
5% CO2 incubator at 37 °C. Harvested cells were washed
three times with PBS and put into 1 ml TRI-reagent (Life
Technologies, USA) for following total RNA isolation.
Leftover PBMC samples from the adherence protocol were
used for DNA isolation.
Nucleic acid isolation, complementary DNA synthesis
and quality determination. RNA from the harvested cells
and from blood donor PBMC was extracted using TRI-
reagent, according to the protocol provided by the manufac-
turer (Life Technologies, USA). The integrity and quality of
isolated RNA was tested in denaturing gel electrophoresis
using NorthernMax™-Gly Gel Prep/Running Buffer (Ther-
moFisher Scientific, USA) according to protocol of the
manufacturer. Complementary DNA (cDNA) was synthe-
sised using the innuSCRIPT One Step RT-PCR SyGreen
Kit (Analytik Jena, Germany). DNA from PBMC was ex-
tracted using the phenol-chloroform method.
The quality of the isolated genomic DNA and synthesised
cDNA, obtained from patient PBMCs and mono-
cytes/macrophages, was determined by beta()-globin po-
lymerase chain reaction (PCR) with appropriate primers
(Vandamme et al., 1995).
Detection of HHV-6 genomic sequences and gene expres-
sion using nested PCR techniques. The HHV-6 genomic
sequence in the DNA isolated from AIT patient PBMC was
identified using nested PCR (nPCR) technique. PCR ampli-
fication of viral DNA was carried out in the presence of
1 µg of PBMC DNA. HHV-6 was identified in accordance
with Secchiero et al., 1995. Positive controls (HHV-6A and
HHV-6B genomic DNA; Advanced Biotechnologies Inc,
Columbia, MD, USA) and negative controls (DNA obtained
from healthy HHV-6 negative blood donor and a sample
without template DNA) were included in each experiment.
To identify active HHV-6 replication, HHV-6 U79/80 gene
expression was determined using nPCR with cDNA as the
template (Kondo et al., 2002), as U79/80 gene coded pro-
teins have a role in viral DNA replication (Taniguchi et al.,
2000). The following primer pairs were used: an outer
primer pair U79/80F2:
5' -CTCGGAGCCCGAGCTACGAAATCTG-3' and
U79/80R2: 5' -GCAACAAGTCT GGCCCTAAGCTG-3',
and an inner primer pair: U79/80F1:
5' -CGATGAACACAGAAAACGCTCG-3' and U79/80R1:
5' –GTAGAAGTCGGTGC TATGCCATC-3'. The PCR
buffer and other reagents were in the same concentrations as
in the nPCR described below.
To determine HHV-6 U12 and U51 gene expression, nPCR
with cDNA as the template was performed (Kondo et al.,




(for the HHV-6 U12); U51F2:
5’-CATTGCTTCGTTTCTTCGGGATGGAG-3’ and
U51R2: 5’-CGCGAGAAAACACTGTCCAGTCTCG-3’
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(for the HHV-6 U51); as well as an inner primer pair:
U12F1: 5’-CATACAGATCCCCTATATAGCTATC-3’ and
U12R1: 5’-CCTCCAGTGAATGCGTAGACTAACG-3’




All nPCR reactions were done in two rounds, each reaction
had a volume of 50 µl consisting of: 5 µL of the extracted
DNA sample or synthesised cDNA and 45 µL of reaction
mixture (1 × PCR buffer with KCl (Thermo Scientific, Fer-
mentas, Lithuania), 0.2 mM of dNTP (Thermo Scientific,
Fermentas, Lithuania), 15 mM MgCl2 (Thermo Scientific,
Fermentas, Lithuania), 2.5 units of Taq DNA polymerase
(Thermo Scientific, Fermentas, Lithuania) and correspond-
ing primer pairs with the concentration of 0.5 µM). Reaction
was done in 35 cycles (denaturation at 95 oC for 30 s, an-
nealing at 62 oC for 30 sec, and elongation at 75 oC for 1
min) for two rounds. A 10-min additional elongation step
was done after the last cycle to ensure complete polymerisa-
tion.
HHV-6 load determination using quantitative PCR. AIT
patient PBMC DNA samples that were positive for the pres-
ence of HHV-6 genome sequence were used for HHV-6
load detection using the HHV-6 Real-TM Quant (Sacace
Biotechnologies, Italy) commercial kit in accordance with
the manufacturer's instructions.
Statistical analysis methods. All statistical calculations
and graphs were created using GraphPad Prism software
version 6.0 for Windows (GraphPad Software, San Diego,
CA, USA). Statistical differences in the prevalence of
HHV-6 infection were assessed by the Fisher exact test.
Statistical differences in viral load and serological results
were tested using the Mann–Whitney test. Because most of
the data was not distributed normally, results are expressed
as median and interquartile range as a variability character-
istic, and a p-value less than 0.05 (p < 0.05) was considered
as statistically significant.
RESULTS
Detection of HHV-6 persistent infection in AIT patients'
and blood donors' PBMC. HHV-6 genomic sequence fre-
quency was significantly higher (p = 0.0001) in AIT patient
PBMC DNA samples (24 out of 73; 33%) in comparison to
those of blood donors (6 out of 80; 7%) (Fig. 1).
Detection of HHV-6 active infection (HHV-6 U79/80
gene expression). Markers of active HHV-6 infection
(presence of HHV-6 U79/80 mRNA) were found in 8 of 73
(11%) monocyte/macrophage RNA samples acquired from
AIT patients. From 24 patient samples positive for the
HHV-6 genomic sequence, 33% contained markers of ac-
tive HHV-6 infection. It was not possible to harvest blood
donor PBMC for monocyte/macrophages in adherence to
the protocol, as blood donor PBMC samples were collected
and stored in Tri-reagent before this study. That is why
blood donor total RNA for active HHV-6 infection marker
detection was isolated from PBMC. HHV-6 U79/80 mRNA
was not found in any of the 6 blood donor samples positive
for the HHV-6 genomic sequence (Fig. 1).
Detection of HHV-6 U12 and U51 gene expression.
HHV-6 U12 mRNA was not found in any AIT patient or
blood donor samples. HHV-6 U51 mRNA was found only
in two out of 24 (8%) AIT patient samples positive for the
HHV-6 genomic sequence. None of the blood donor sam-
ples were positive for HHV-6 U51 mRNA.
Detection of HHV-6 load. Sensitivity of the HHV-6 Real-
TM Quant (Sacace Biotechnologies, Italy) commercial kit is
about 5 viral copies. Detectable HHV-6 load was found in
only 6 of 24 (25%) AIT patient samples previously deter-
mined to be positive for the HHV-6 genomic sequence. The
median HHV-6 load found in AIT patient samples was
5.246 (IQR: 2.026–21.41) viral copies/106 cells. In contrast,
no detectable HHV-6 load was found in blood donor sam-
ples (Fig. 2).
Only two of AIT patient samples that were positive for at
least one of HHV-6 mRNAs (U12, U51 and/or U79/80)
were with detectable viral load. Two samples positive for
HHV-6 U51 mRNA had a viral load of 6.090 and 4.400
copies/106 cells.
DISCUSSION
From the beginning it was postulated that HHV-6 is a lym-
photropic virus with primary tropism for CD4+ T cells, in
which they replicate efficiently (Dockrell and Paya, 2001;
Lusso, 2006). Later studies indicated the ubiquitous nature
of HHV-6 and showed that HHV-6 genomic sequence could
be found in almost every solid tissue and other peripheral
blood subpopulations including monocytes/macrophages
(Kondo et al., 2002; Chen and Hundall, 2006; Caselli et al.,
2012).
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Fig. 1. Presence of human herpesvirus-6 (HHV-6) genome sequence and
HHV-6 U79/80 mRNA (marker of active infection) in autoimmune
thyroiditis (AIT) patient samples and blood donors (control group).
For HHV-6 active infection, viremia is not typical and oc-
curs only in acute cases, as the virus in most cases spreads
from cell to cell. HHV-6 U51 is shown to be a positive
regulator of virus replication in vitro, and may promote
membrane fusion facilitating cell-cell spread of this highly
cell-associated virus (Zhen et al., 2005). Such spread tactics
could help HHV-6 to effectively escape immune responses
and provoke autoimmune reactions (Mothes et al., 2010).
One study showed that during acute infection HHV-6 uses
mainly monocytes/macrophages for the spread and ex-
presses viral chemokine receptors U12 and U51, which
might help to avoid immune responses. Monocyte/macro-
phage migration into an inflammation site might facilitate
infection of solid tissues (Kondo et al., 2002). This makes
monocytes/macrophages important mediators in delivering
HHV-6 to its final destination, where the virus could per-
sist.
Nowadays, more evidence indicates HHV-6 as a very im-
portant factor in AIT development (Rizzo et al., 2016;
Caselli et al., 2017; Sultanova et al., 2017). Our previous
studies showed almost 100% incidence of the HHV-6 ge-
nomic sequence in thyroid gland tissues acquired from AIT
patients and insignificant presence in peripheral blood (Sul-
tanova et al., 2016; 2017). Also, in-depth study on PBMC
subpopulation cell sorting showed absence of HHV-6 ge-
nomic sequence in primary target cells — CD4+ and CD8+
T lymphocytes (Sultanova et al., 2016). The aim of this
study was to investigate the possible use of monocytes/
macrophages as mediators by HHV-6 for thyroid gland in-
fection in the case of autoimmune thyroiditis. The results of
this study show significantly higher presence (p = 0.0001)
of HHV-6 genomic sequences in AIT patient PBMC sam-
ples than in the control group (33% vs 7%, respectively),
and in addition presence of the HHV-6 active infection
marker (HHV-6 U79/80 mRNA) was found only in AIT pa-
tient monocyte/macrophage samples (8 out of 24; 33%).
That means that HHV-6 has relatively higher activity in
AIT patient monocytes/macrophages than in healthy indi-
viduals. The obtained results on viral load also support this
statement. In the majority of HHV-6 positive PBMC sam-
ples we were unable to determine the viral load, but this can
be considered as normal for HHV-6. Guidelines for virus
testing published on the HHV-6 Foundation website
(Anonymous, 2019) indicate that its load usually is not de-
tectable in peripheral blood.
Only two AIT patient samples were positive on HHV-6 U51
mRNA. Nevertheless, involvement of expression of this
gene in AIT development cannot be excluded.
Overall, the results of this study indicate the possibility of
monocytes/macrophages being used by HHV-6 as media-
tors for thyroid gland infection and their potentially impor-
tant role in AIT development. However, to make final con-
clusions additional study is required.
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MONOCÎTI/MAKROFÂGI DARBOJAS KÂ MEDIATORI VAIROGDZIEDERA AUDU INFICÇÐANÂ AR HHV-6 AUTOIMÛNÂ
TIREOIDÎTA PACIENTU VIDÛ
Ðî pçtîjuma mçríis bija izpçtît cilvçka herpesvîrusa-6 (HHV-6) spçju izmantot monocîtus/makrofâgus kâ mediatorus vairogdziedera audu
inficçðanâ autoimûnâ tireoidîta (AIT) pacientu vidû. Pçtîjumâ tika iekïauti 73 pacienti ar autoimûno tireoidîtu. Kontroles grupu veidoja 80
asins donori. Tika veikta perifçro asiòu mononukleâro ðûnu (PBMC) izolâcija, un AIT pacientu gadîjumâ tâlâk tika atdalîti
monocîti/makrofâgi, izmantojot ðûnu adhçziju. HHV-6 klâtbûtne PBMC DNS paraugos tika detektçta, veicot nested PCR (nPCR). AIT
pacientu monocîtu/makrofâgu paraugiem un asins donoru PBMC paraugiem aktîvâs infekcijas maríieru (U79/80) un hemokînu receptoru
(U12 un U51) gçnu ekspresija tika noteikta, veicot reversâs transkripcijas PCR. HHV-6 slodze tika noteikta, izmantojot kvantitatîvo-PCR.
HHV-6 genoma klâtbûtne autoimûnâ tireoidîta pacientu paraugos tika detektçta ievçrojami bieþâk, salîdzinot ar asins donoru paraugiem.
Aktîvas infekcijas maríieri tika atrasti 8 (11%) autoimûnâ tireoidîta pacientu monocîtu/makrofâgu paraugos un nevienâ no kontroles grupas
PBMC paraugiem. Lîdzîgi arî HHV-6 U51 mRNS tika atrasta tikai autoimûnâ tireoidîta pacientu vidû — 2 no 24 (8%) HHV-6 pozitîvajiem
paraugiem. Tâ kâ HHV-6 genoma sekvenèu klâtbûtne ievçrojami bieþâk tika detektçta autoimûnâ tireoidîta pacientu paraugos un aktîvas
infekcijas maríieri tika atrasti monocîtos/makrofâgos, pçtîjuma rezultâti norâda uz iespçjamo monocîtu/makrofâgu kâ mediatoru lomu
HHV-6 infekcijai vairogdziedzera audos.
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